REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up - Zacks Investment Research
REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up - Zacks Investment Research(摘要待生成)
Regeneron (REGN) Reports Q3 Earnings: What Key Metrics Have to Say - Zacks Investment Research
Regeneron (REGN) Reports Q3 Earnings: What Key Metrics Have to Say - Zacks Investment Research(摘要待生成)
Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates - Zacks Investment Research
Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates - Zacks Investment Research(摘要待生成)
Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?
Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?(摘要待生成)
Why Regeneron Shares Are In Focus After Strong Earnings - Yahoo Finance
Why Regeneron Shares Are In Focus After Strong Earnings - Yahoo Finance(摘要待生成)
Regeneron Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
Regeneron Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance(摘要待生成)
Regeneron (REGN) Q3 2026 Earnings Call Transcript
Regeneron (REGN) Q3 2026 Earnings Call Transcript(摘要待生成)
Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 1-Year High Following Better-Than-Expected Earnings
Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 1-Year High Following Better-Than-Expected Earnings MarketBeat
REGN Stock Hits 2-Year Highs Pre-Market: CFO Says Regeneron Is Positioned To Deliver One Of ‘Strongest Years Ever’ After Q3 Earnings Beat - Yahoo Finance
REGN Stock Hits 2-Year Highs Pre-Market: CFO Says Regeneron Is Positioned To Deliver One Of ‘Strongest Years Ever’ After Q3 Earnings Beat - Yahoo Finance(摘要待生成)
Regeneron Pharmaceuticals, 8-K (2.02, 9.01): reported results of operations
Regeneron reported third-quarter 2026 revenue of $5.116 billion, up 36%, and diluted GAAP and non-GAAP EPS of $18.45 and $20.07, respectively; it also expanded its Sanofi collaboration and said Pasatru was FDA-approved for FOP.
Regeneron Pharmaceuticals earnings beat by $4.01, revenue topped estimates
Regeneron Pharmaceuticals earnings beat by $4.01, revenue topped estimates(摘要待生成)
Regeneron hits 52-week high after “standout” Q3 (REGN:NASDAQ)
Regeneron hits 52-week high after “standout” Q3 (REGN:NASDAQ) Seeking Alpha
Wells Fargo raises Regeneron stock price target to $925 on execution
Wells Fargo raises Regeneron stock price target to $925 on execution(摘要待生成)
REGN Stock Climbs As Libtayo Data And Targets Rise - StocksToTrade
REGN Stock Climbs As Libtayo Data And Targets Rise - StocksToTrade(摘要待生成)
Regeneron Stock Jumps As Libtayo Data Fuels Bullish Targets - StocksToTrade
Regeneron Stock Jumps As Libtayo Data Fuels Bullish Targets - StocksToTrade(摘要待生成)
REGN Stock Jumps As Bullish Data And Targets Pile Up - StocksToTrade
REGN Stock Jumps As Bullish Data And Targets Pile Up - StocksToTrade(摘要待生成)
Regeneron Eyes One of Its Strongest Years Ever, Stock Jumps - Benzinga
Regeneron Eyes One of Its Strongest Years Ever, Stock Jumps Benzinga
Regeneron Surges 13.55%: Here’s What It Means for Your Health Care ETFs
Regeneron Surges 13.55%: Here’s What It Means for Your Health Care ETFs Yahoo Finance
Regeneron Pharmaceuticals stock hits 52-week high at $869.43 By Investing.com - Investing.com South Africa
Regeneron Pharmaceuticals stock hits 52-week high at $869.43 By Investing.com Investing.com South Africa
Canaccord Genuity Adjusts Price Target on Regeneron Pharmaceuticals
Canaccord Genuity has revised its price target for Regeneron Pharmaceuticals, increasing it from $875 to $922.